Has Sara Baig, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,118 in general payments to Sara Baig, MD across 23 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sara Baig, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sara Baig, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sara Baig, MD

Rheumatology · Edina, MNNPI 1891182069

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,680 of the $2,118 with a category attached, or 79.3%. Johnson & Johnson accounts for 86.4% of it on its own, with 6 other manufacturers making up the rest. 2024 is the largest year on record at $1,832, more than ten times the $14 reported in 2019.

$2,118in general payments, 2019–2025

Across 23 payments — averaging $92.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$2K
E.r. Squibb & Sons, L.L.C.$204
Sanofi$32
Amgen$17
Aurinia Pharma U.S., Inc.$16
Pfizer$14
plus $7 from 1 others

What the payments were for

Consulting fees$1,68079%
Food & beverage$43821%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	3	$1,829
E.r. Squibb & Sons, L.L.C.	13	$204
Sanofi	2	$32
Amgen	1	$17
Aurinia Pharma U.S., Inc.	1	$16
Pfizer	1	$14
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$1,816

How this compares

$2,118 in reported general payments places this provider in the 75th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$958,010

Medicare patients

312

Services billed

62,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EnbrelEtanercept	40	$298,296
Enbrel SureclickEtanercept	18	$167,403
Humira(Cf) PenAdalimumab	14	$121,981
SimponiGolimumab	18	$120,281
Cosentyx (2 Syringes)Secukinumab	13	$91,775
Orencia ClickjectAbatacept	12	$78,946
OlumiantBaricitinib	11	$29,654
Hydroxychloroquine Sulfate	342	$15,330
MethotrexateMethotrexate Sodium	433	$14,086
Cevimeline Hcl	37	$12,429
Pilocarpine Hcl	60	$6,718
Mycophenolate Mofetil	29	$5,568
Celecoxib	109	$5,555
Sulfasalazine DrSulfasalazine	71	$4,922
Leflunomide	70	$3,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenEnbrel	$17	$298,29640 claims
Johnson & JohnsonSimponi	$1,829	$120,28118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 121 rheumatology providers in Minnesota.

Other rheumatology in Edina

Jeffrey WilsonEdina$49K
Joshua WaytzEdina$2K
Grace Skemp-DymondEdina$2K
Angela DahleEdina$1K
Kurt ZimmermanEdina$1K
Susan LeonardEdina$485
Walter DormanEdina$403
Hammad BajwaEdina$248
Donna FontanaEdina$191
Anne WolffEdina$184

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →